On this page
Decnupaz
pivekimab sunirine-pvzy
351(a) Standalone BLA
Overview
Source: Purple BookProprietary name
Decnupaz
Proper name
pivekimab sunirine-pvzy
Licence type
351(a)
BLA number
761460
Applicant
AbbVie Inc.
Center
CDER
Presentations
1
First licensure
—
Presentations
Source: Purple Book| Strength | Dosage form | Route | Presentation | Status | Licensed |
|---|---|---|---|---|---|
| 2MG | For Injection | Intravenous | Single-Dose Vial | Rx | May 27, 2026 |
Sources for this page
| Purple Book | FDA | Licence type, presentations, reference product, exclusivity |